Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Global PD-1 and PD-L1 Inhibitors Market 2019-2023

Read the 118-page research report with TOC on "PD-1 and PD-L1 Inhibitors Market Analysis Report by Application (Solid tumors and Blood-related tumors), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023". This led to the approval of KEYTRUDA in September 2014, driving growth in the oncology therapeutics market. In clinical trials, PD-1 and PD-L1 inhibitors have shown higher overall survival rate (OSR), objective response rate (ORR), and progression-free survival (PFS) in patients with cancer such as melanoma and NSCLC. PD-1 and PD-L1 inhibitors are also used to inhibit cancer cells and reverse the damage caused by blocking the pathway that helps in cancer cell multiplication. As a result, most of the PD-1 inhibitor drugs are approved for cancer indications such as Hodgkin lymphoma, urogenital cancer, and NSCLC because they have high safety profile.

First found on: And then on: 3 other references